Cancer remains a leading cause of mortality globally, and its yearly death toll of 8.2 million people is only anticipated to rise as the world's population ages. The presence of tumor-associated inflammatory cells in cancers poses a critical concern that is one of oncology's most pressing issues. Immunotherapy, which targets the immune system, has revolutionized cancer treatment in the previous decade. Many important questions about the causal relationship between chronic inflammation and carcinogenesis have been answered by immunological tests over the last two decades. Recent clinical and preclinical research has begun to reveal the wide range of systemic immune perturbations that occur during cancer development, and the critical role of peripheral immune cells in the anticancer immune response.
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title : Biosensor-based detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Hospital care for cancer patients - safety, quality of care, education and respect for patient’s rights
Mariola Wioletta Borowska, Maria Sklodowska-Curie National Research Institute of Oncology, Poland
Title : Importin7 induces M2 macrophage and promotes the progress of colorectal cancer by regulating the nucleus translocation of GRP78
Changjiang Yang, Peking University People's Hospital, China
Title : Cancer-associated fibroblasts derived soluble CADM1 predicts response to neoadjuvant chemoimmunotherapy in lung cancer
Jian Li, Shanghai Jiaotong University, China
Title : Chalepin suppresses cell growth by down-regulation of the epidermal growth factor receptor downstream pathways and induced cell cycle arrest in MCF7 breast cancer cells
Isah Musa Fakai, Kebbi State University of Science and Technology, Nigeria